Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database.

Advances in therapy·2026

Same author

Nitrous oxide abuse prevalence, mechanisms, treatments and prevention.

Current medical research and opinion·2026

Same author

Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026

Same author

Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.

The Annals of pharmacotherapy·2026

Same author

Expanding access and comprehensive care in the management of patients with inflammatory bowel disease with pharmacy services.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health.

Public health reports (Washington, D.C. : 1974)·2026

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The relationship between statin use and atrial fibrillation.

Aarti A Patel¹, C Michael White, Sachin A Shah

¹University of Connecticut School of Pharmacy, Storrs, CT, USA.

Current Medical Research and Opinion

|May 24, 2007

Summary

Statin therapy significantly reduced the odds of developing atrial fibrillation (AF), including new-onset, recurrent, and postoperative types. These findings suggest statins offer benefits beyond lipid-lowering effects.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: Jul 14, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Cardiology
Pharmacology
Epidemiology

Background:

Atrial fibrillation (AF) is a common cardiac arrhythmia with significant health implications.
Statin therapy is widely used for cardiovascular risk reduction, primarily through lipid modification.
The potential role of statins in modulating AF incidence requires further investigation.

Purpose of the Study:

To systematically evaluate the association between statin therapy and the development of atrial fibrillation.
To analyze the impact of statins on new-onset, recurrent, and postoperative AF.
To determine if statins provide benefits beyond their known lipid-lowering effects.

Main Methods:

A systematic literature review and meta-analysis of randomized controlled trials and observational studies.
Studies published up to September 2006 were included, comparing patients on statin therapy versus those not.
Weighted averages were calculated as odds ratios (OR) with 95% confidence intervals (CIs) using a random-effects model.

Main Results:

Fourteen trials comprising 15 analyses (n=7402) were included in the meta-analysis.
Statin use was associated with a 45% reduction in the odds of any AF (OR 0.55; 95% CI 0.43-0.70).
Significant reductions were observed for new-onset AF (32%), recurrent AF (57%), and postoperative AF (58%).

Conclusions:

Statin therapy demonstrates a significant association with reduced odds of developing atrial fibrillation.
The findings support a cardioprotective role for statins independent of their lipid-lowering properties.
Limitations include potential publication bias and the inclusion of observational studies and abstract-only data.